Figure 1 shows how the technology can be adapted for cancer research to assess the migration and invasion of cancerous cells in real-time. Figure 2 shows how the same readout can be applied to functional detection of iPS-derived cardiomyocytes and detection of compounds, which may cause arrhythmia.
These two aforementioned applications are just a small example of the flexibility and diversity of the readout and applications. It is perhaps not a surprise that the xCELLigence system is being utilized by researchers in academic basic research in such diverse fields as cancer, immunity, inflammation, and infection. In addition, because of the diversity of applications, the technology has been well integrated into the drug discovery and development process from target validation, assay development, lead generation and optimization as well as preclinical toxicology and safety evaluation of compounds.
Based on a solid foundation of science, innovation, and commercialization, ACEA looks forward to the next 10 years as it plans to diversify its product portfolio into other areas of cell analysis, drug discovery and development, diagnostics, and the healthcare field in general.